
$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

French ImCheck get´s a USD103m check by Pfizer and a pack of VCs
With around EUR100m in previous financing rounds ImCheck’s financial position looks 'solidified' to take on the leadership in the gamma-delta T cell...

G7 heads call for decarbonisation of industry
The G7 ministers underlined the importance of efforts to improve energy efficiency, the need for increased investment in renewable energy, tracking...

Hansa Biopharma’s imlifidase advances to Phase III testing
According to Lund-based Hansa Biopharma AB the study protocol has been greenlighted both by the FDA and the European Medicines Agency (EMA), so its...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Replacing beef with cellular protein halves deforestation
As the negative environmental impacts of ruminant meat consumption become more evident — including those concerning greenhouse gas...

Sanofi and IGM Biosciences Inc. in $6.15bn deal
Under the agreement, IGM Biosciences Inc. (Mountain View) will discover IgM antibody agonists against three oncology targets and...